NZNO Women's Health College NCSP HPV Update - 11 May 2024

Nadine Riwai (MN, RN)

Ngati Porou, Te Aitanga a Mahaki, Te Uri o Hau, Ngai Takoto

Senior Relationship Manager

National Cervical Screening Programme

Why did we change to HPV primary screening?

HPV primary screening detects the Human Papillomavirus, which causes 99% of cervical cancers.

Cytology looks for cell changes. HPV causes those cell changes.

HPV primary screening determines if a cytology test or referral to Colposcopy is required.

NOTE

- HPV self-testing is not an automatic blanket test for everyone.
- Some will require cytology if under surveillance, needing a Test of Cure, or if clinically indicated

HPV primary screening

Human papillomavirus (HPV) is a **virus** that infects the skin and mucous membranes.

HPV is passed on by intimate skin-to-skin contact during sexual activity.

It's extremely common – **four out of five adults** will come into contact with HPV.

There are **many types** of HPV.

HPV primary screening tests for the 14 oncogenic types which cause cancer.

The most high-risk types of HPV are 16 and 18.

Persistent infection with oncogenic HPV is the **risk factor** for cancer.

Cervical Screens since the HPV launch

130,000 screens

80%

Were HPV Self-tests


20.2%

Were Unscreened / Under screened participants 2.1%

Results had HPV 16/18 7.9%

Results had HPV Other

Coverage




Ethnicity	Screens	%
Maori	124,788	58.9%
Pacific	55,590	60.8%
Asian	167,472	66.4%
Other	618,005	76.1%
All	965,855	70.6%

Screens to reach equity

Ethnicity	Screens	
Maori	36,625	
Pacific	14,009	
Asian	24,666	
Other	0	
All	75,300	

Screens to Reach Equity in Up-to-Date Coverage, by Ethnicity, New Zealand, Apr 2019 to Mar 2024



HPV Modules

Module 1 | Introduction to Cervical Screening Using Human Papillomavirus (HPV) Testing

Part 1 of the Cervical Screening learning programme.

This 60-minute module will provide you with an overview of cervical screening in Aotearoa New Zealand, introduce the new Clinical Practice Guidelines for cervical screening, and will help you understand HPV and its role in the development of cervical cancer, HPV vaccination, and HPV testing and pathways.

Module 2 | Navigating the Cervical Screening pathways – practising using the pathways with various cases Part 2 of the Cervical Screening learning programme.

This 30-minute module presents a series of examples of how to interpret the cervical screening pathways in the Clinical Practice Guidelines for Cervical Screening in Aotearoa, New Zealand. It then presents a further 13 scenarios to give you a chance to check your understanding and apply the guidelines to each situation.

Module 3 | Cervical Screening in Aotearoa New Zealand – History and Context

Part 3 of the Cervical Screening learning programme.

This 30-minute module provides an overview of the National Cervical Screening Programme (NCSP Register and the history of the NCSP. It also covers the persisting inequities in cervical screening and how aligning with the new health reforms and reflecting on practice can improve health equity.

Module 4 | Talking about Cervical Screening and HPV

Part 4 of the Cervical Screening Learning programme.

This 60-minute module covers what you need to know to talk to your patients about HPV primary screening. It covers barriers to screening, how to have culturally-safe and effective conversations about cervical screening, and how to share test results with your patients.

Workforce expansion

Since November 2023, nurses who are not cervical screen takers can complete training and enter a professional partnership with a cervical screen taker to offer HPV screening.

Work is underway to expand the workforce further this year — initially to Kaimahi in Screening and Support services and NCSP Regional Coordination teams.


Workforce expansion

HPV Screen takers must complete the following learning pathway prior to facilitating HPV self-testing with participants.

- 1. Establish a professional partnership with a responsible clinician who will be available to provide clinical support, take responsibility for results requiring follow-up or referral, and undertake follow up liquid-based cytology (LBC) sample taking.
- 2. Complete the four NCSP Cervical Screening with Human Papillomavirus (HPV) testing training modules.
- 3. Be familiar with the updated <u>National Cervical Screening Programme Policies and Standards Section Three: Cervical Screening Services</u> and the <u>Clinical Practice Guidelines for Cervical Screening in Aotearoa New Zealand</u>.
- 4. Complete a professional partnership assessment and agreement with the nominated responsible clinician.

HPV screen-taker pathway

For Nurses who are not cervical screen-takers



Clinical Practice tips

Participant choice

Whether participants choose to self-test or opt for a cervical sample (smear) they must be offered the choice. All screening options must be provided as part of the informed consent process.

Let participants know to expect an enrolment letter.

Once a participant has had their first screen and has agreed to be enrolled in the NCSP, their test is sent to the Register, and an enrolment letter is sent. It is important to let participants know to expect an enrolment letter from the NCSP confirming their participation in the programme. This helps ensure they are aware of their involvement in the screening process and that their results are recorded on the NCSP Register.

Clinical Practice tips

Ovestin option before screening or colposcopy

Post-menopausal participants and participants with atrophy associated with progesterone contraception or testosterone therapy may benefit from Ovestin cream prior to screening or colposcopy. This is to improve the accuracy of cytology and colposcopy and make it more comfortable for the participant. Check your local health pathway for details.

Recalls and Reminders

It's important to continue to send recalls and reminders to your patients at a local level.

Clinical Practice tips

Finding under-screened and unscreened participants

Under-screened and unscreened patients make up 85% of cervical cancer cases. You can find a list of your under-screened and unscreened patients by using the PHO Cervical Screening Status Report, which is sent to PHOs monthly. This list can be filtered by due date and ethnicity, so that you can quickly find priority patients. We will have a guidance list out to all PHOs soon with more scenarios in how to best filter your report.

If you can't access this list, please contact your PHO or NCSP regional coordinator. You can contact your regional coordinator by calling 0800 729 729.

Module to support HPV korero with participants

Module 4 | Talking about Cervical Screening and HPV

Part 4 of the Cervical Screening Learning programme

This 60-minute module covers what you need to know to talk to your patients about HPV primary screening. It covers barriers to screening, how to have culturally safe and effective conversations about cervical screening, and how to share test results with your patients.

Course: Cervical Screening Using Human Papillomavirus (HPV) Testing Programme (learnonline.health.nz)

What does HPV mean?

- Human papillomavirus is a virus that infects the skin and mucous membranes.
- HPV is passed on by intimate skin-to-skin contact during sexual activity

Why has the test changed?

- HPV primary screening tests detect the presence of the Human Papillomavirus, which causes 99% of cervical cancers.
- Cytology (aka smear test) looks for cell changes.
- HPV looks for the presence of the virus that causes those cell changes
- Determines if someone needs a cytology test or referral to Colposcopy

Can I still have a smear?

- Yes, it is your choice what test you want to have.
- An HPV self-test, an HPV test taken by your Dr/Nurse, or a cytology (smear).

Why won't my smear be tested for cytology?

- HPV is tested first, and if it is detected, your smear sample will be retested for cytology.
- If HPV is not detected, there is no need to retest the smear sample.
- HPV is a more sensitive test; HPV is the main cause of cell changes that cytology tests for.

I've had normal smears for years, and now I have HPV. What does that mean?

- Smears were never automatically tested for HPV before. We now know that HPV is the main cause of cervical cell changes. We test for HPV first as a sensitive prevention screening test.
- A person may have had HPV for many years but had never been tested for it until now.
- Cervical cancer often takes 10 or more years to develop. With regular screening, abnormal cells can be found and treated early before they become cancer.
- The HPV screening test can detect cell changes very early. Most people will only need to have an HPV screening test every five years.

There are many different types of HPV, and some are more likely than others to lead to cervical cancer.

The body is pretty good at clearing the virus itself, usually within 2 years, especially in people under 30. However, sometimes it can persist and may develop into cervical cancer over time. 95% of cervical cancers are caused by HPV.

People with HPV usually:

- Do not have symptoms
- Do not know they have it
- Have no problems or complications

Google says HPV is an STI, has my partner cheated on me?

- No, even people who have not had sexual intimate contact for many years can test positive for HPV.
- HPV does not mean that a person or their partner is having relations outside their current relationship.

About 4 out of 5 adults will have HPV at some time in their lives. It is spread through intimate skin-to-skin contact and any sexual activity. While HPV often clears up by itself, it can stay dormant in your system and my not be detected until years after you came into contact with it. If found in a test, this may not be due to a new exposure with HPV. This is why regular, ongoing screening is still important even if you have been with the same partner, or not been sexually active for some time.

Can I have the HPV vaccination?

- The HPV vaccine is free for anyone aged 9-26 years (even if you get the first dose the day before your 27th birthday).
- You can still get the HPV vaccination from age 27 to 45 at a cost of approximately \$600 for the three doses.

Gardasil-9 is the current vaccine, which includes

• 7 high-risk HPV types (16, 18, 31, 33, 45, 52, 58) and 2 HPV types against genital warts (6, 11).

However, there are 14 oncogenic types tested for in HPV screening.

This is why both vaccination and screening are needed.

Resources


<u>Cervical screening - Healthed</u>


CERVICAL SCREENING


















Dispose of any leftover materials in the rubbish pin, then wash your hands

Step 8.



Place the completed sample and form back into the bag, seel it and give it



Te Whatu Ora Te Aka Whai Ora

Resources

<u>Cervical screening - Healthed</u>









Māori Health Authority



MATAWAI WAHA KŌPŪ Te mahi i te whakamātau-whaiaro

tipako whalaro ki tō te tipako a te kalishakarato f tawa te tüponotanga e hii ai äu mahi. He call not to what tonu I to what smittau mehames:

kus pā ngā matikara ki te pito ūkui o te tipani jahakos he pai

kua uru te tipani ki roto i te tara, engari kāpre kos i te mõhip

haugra hei tong i ta kete whakamiltau-whaising hou hei



Ka ilwhina te aratohu nei i a koe kia tiki koe ake i te tipako tara. Mehemes he äwangawanga du i te whakamatau ranei, i te aha rā rānei, tēnā, inois atu te āwhins i tōu kalwhakarato hauora.



hostu te kete whakamiltau ki a koe me ngă sohutohu taipitopito hei mahi atu. Mohemes he piltai riinei, he hanga usus

Ne whakatau rawa te tika o čiu ake talpitopito i te waltohu me te puka haugra, å, me täpiti ngä mea e hipa ana. Târă pes he mes and hei whakaki atu, hi përë me te rë whakamiltau.



Mahi 1.

Harala nali riinas ki te haai me te wai



Ka aha ina hê te mahi?

ake mehemes kliore / pli stu)

mehemea kus rahi te urunga ake.

Mahi 2.

Mahi 4.

Kei roto i te withi türnataiti, whirih is sas roco-se water turnisast, amerika te taunga e pai ana hel tild i te tipako. Heli pea ka noho (linei, ka til ränei, ka takoto ränei, ka koromeke ränei. Ki te kore koe e tangatanga i sétahi, knole atu te Swhine o tôu

whakatuhera i te tara, ka šta whakauru al i te pito o te tipani ki roto kia 4-5 hin (he përë me të roa a te kônui, ënd kei

Ki ta muinga o ngā tāngata, he mea ngāwari, he mea hāneanea. Ino mamae, me šta unu rānei te tipani kia tangatanga ai, me inci rānei ki tāu kalwhakarato haupra kia šerhina atu

Hel te tangohange iho i te tipako, ata tirahia ngli tahutahu a te kete hei whakaoti i te whakamilitau.



Mahi 3.

Unuhis te ngongo mau tipani i te pëke. Klitahi ka unuhis te tipani i te ngongo. Tërë pes me pupuri te ngongo, ka whakshurihuri si i te kōpani hei tihse.

Tënd, kia tüpato keli pili atu te pito o te tipani ki ngli matikata ränel, ki tiftahi aha ränel.



Mahi 5.

Hurihurihia te tipani kia 4 ngā wā (e 20 hilkona paa te rosi, me te āta hārau atu ki ngã taha o te tara, kātahi ka



Mahi 7.

Whakardres ngà toenga ki te ipu para. ka hárol si i ngá ringaringa ki te hapi me te wai, kikahi ka tauera kia morok




Mahi 8.


Mahi 6.

Purus te tipako me te puka hauora ki roto i te pilka, ka heres ai Kilitahi ka whakahokia ki tibu kaleihakarato

Te Whatu Ora Te Aka Whai Ora

Resources





<u>Cervical screening – Healthed</u>





Staying up to date with the NCSP

- NCSP Sector Update sign up
- Time to Screen <u>www.timetoscreen.nz/cervical-screening</u>
- Health NZ Te Whatu Ora <u>Understanding HPV Primary</u>
 <u>Screening Health New Zealand | Te Whatu Ora</u>
- NCSP Policies and Standards Section 3: <u>Cervical Screening</u> <u>Services</u>

Nga mihi Does anyone have any pātai / questions?

Nadine Riwai Nadine.Riwai@Tewhatuora.govt.nz

